316 Participants NeededMy employer runs this trial

Novosis Putty for Degenerative Disc Disease

Recruiting at 9 trial locations
JH
Overseen ByJumi Han
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called Novosis Putty for individuals with lumbar degenerative disc disease, a condition where lower back discs deteriorate, causing pain. The study aims to evaluate the safety and effectiveness of Novosis Putty in a specific type of back surgery. Participants will receive either Novosis Putty or the standard treatment to compare outcomes. Those who have experienced lumbar degeneration symptoms and have not found success with other treatments for at least six months may be suitable for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the potential availability of a new treatment.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that Novosis Putty is safe for treating lumbar degenerative disc disease?

A previous study found Novosis Putty to be safe for patients undergoing spinal fusion surgeries. Patients generally tolerated the treatment well, with no serious side effects directly linked to the putty. Some reported minor side effects, such as mild pain at the application site, but these were manageable and resolved quickly.

Research has shown that Novosis Putty, which contains a protein to aid bone growth, has been tested in several groups. These studies consistently found the treatment safe for similar procedures. The FDA has also given special recognition to the putty, highlighting its potential as a safe option for spine-related treatments.

Overall, current data suggests the treatment is safe. This information may provide reassurance for those considering participation in a trial with Novosis Putty.12345

Why do researchers think this study treatment might be promising?

Unlike standard treatments for degenerative disc disease, which often include pain relievers, physical therapy, or surgery, Novosis Putty presents a novel approach. Researchers are excited about this treatment because it uses a unique biomaterial designed to promote tissue regeneration and repair within the spinal disc itself. This could potentially provide longer-lasting relief and improve spinal function by addressing the underlying cause of disc degeneration, rather than just managing symptoms.

What evidence suggests that Novosis Putty might be an effective treatment for degenerative disc disease?

Research has shown that Novosis Putty, which participants in this trial may receive, is designed to strengthen bones while preventing unwanted bone growth elsewhere. It contains a special protein called rhBMP-2, which aids in bone healing, and a ceramic material that supports bone growth. Studies indicate that this combination can help spinal bones fuse together. This is crucial for individuals with degenerative disc disease, where the spine's discs wear down and cause pain. The putty releases the protein slowly, potentially enhancing bone healing over time.14678

Are You a Good Fit for This Trial?

This trial is for adults aged 21-80 with lumbar degenerative disc disease who have tried other treatments for at least 6 months without success. Participants must be able to follow study instructions and not have certain health conditions, allergies to the treatment, or recent cancer.

Inclusion Criteria

My Oswestry Disability Index score is 40 or higher.
Signed informed consent
I have tried non-surgical treatments for at least 6 months without success.
See 3 more

Exclusion Criteria

Lactating, pregnant or interested in becoming pregnant in the next 3 years
Is currently participating in an investigational therapy (device and/or pharmaceutical) within 30 days prior to entering the study or such treatment is planned during the 24 months following enrollment into the study
Known hypersensitivity or allergy to any components of the study treatments inclusive of hypersensitivity or allergy to any BMP-2 type recombinant proteins or peptides
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo Transforaminal Lumbar Interbody Fusion surgery using Novosis Putty

Intraoperative

Follow-up

Participants are monitored for safety and effectiveness after treatment

60 months
Regular visits at 6 weeks, 3, 6, 12, 24, 36, 48, and 60 months

What Are the Treatments Tested in This Trial?

Interventions

  • Novosis Putty

Trial Overview

The study compares Novosis Putty, a bone graft material, to standard care in patients undergoing transforaminal lumbar interbody fusion surgery for degenerative disc disease. Participants are randomly assigned to one of the two groups.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Novosis PuttyExperimental Treatment1 Intervention
Group II: Standard of CareActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

CGBio Inc.

Lead Sponsor

Trials
5
Recruited
610+

CGBio USA

Collaborator

Citations

CGBIO Receives FDA IDE Approval for NOVOSIS PUTTY, ...

This system is engineered to enhance high-density bone formation while minimizing ectopic bone growth, a common adverse effect in earlier rhBMP- ...

2.

novonesis.com

novonesis.com/en

Novonesis

Novonesis is a leading global biosolutions company formed through a combination of Chr. Hansen and Novozymes.

Efficacy and Safety of Novosis Putty for Degenerative ...

This clinical study aims to evaluate the efficacy and safety of NOVOSIS PUTTY for bone fusion in patients requiring posterior instrumentation and transforaminal ...

Novosis – CGBIO_EN

Ideal Solution for Bone growth. Indication: Osteogenesis, Osteoconduction, Osteointegration. Accelerates bone growth.

Efficacy and Safety of Novosis Putty in Transforaminal Lumbar ...

Symptomatic lumbar degeneration (L1 to S1) that may be associated with a co-morbid condition. Has a history of failure conservative treatment (e.g. bed rest ...

Synergistic enhancement of spinal fusion in preclinical models ...

The final Novosis Putty is designed to contain 0.4 mg of rhBMP-2 per volume (cc) of bone graft material. Novosis Putty is an injectable, putty ...

Efficacy-and-Safety-of-Novosis-Putty-in-Transforaminal ...

Feedback / Questions. Novosis (bongros/BMP-2) - Daewoong Pharma. http://clinicaltrials.gov/ct2/show/NCT07017634. Feb 21, 2026. SHARE THIS.

Novosis Putty vs Standard Care for Lumbar Fusion - ICH GCP

This clinical trial is evaluating the efficacy and safety of Novosis Putty compared to standard bone graft in patients undergoing ...